Stefan Oschmann, EFPIA President, Chairman of the Executive Board and CEO of Merck
Since the UK public voted to leave the European Union, the potential impact on our healthcare systems has begun to loom large. For most sectors, the issues around Brexit are economic. But medicines are different. As the research-based pharmaceutical industry, the medicines we make improve the quality of life, often save the lives of patients in the UK and across Europe. For us, the primary concern around Brexit has always been patient safety and public health, in particular the uninterrupted supply of medicines to patients in the 27 EU Member States and the United Kingdom.
Read more
The falsification of medicines has remained a serious threat to public health in the EU for too long. As of 9 February...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.